All News

A young father faces a potential lymphoma diagnosis, revealing how medical language, restraint, and rapid coordination reshape care and ease uncertainty.

A total of 48.0% of patients treated with duvelisib experienced a response, 33.3% of whom experienced a complete response.

CancerNetwork, AJMC, and Pharmacy Times are producing The Bispecifics Network, where Ralph V. Boccia, MD, FACP, breaks down the importance of this initiative.

The new guidelines address 11 key clinical questions for optimizing communication between clinicians and patients with cancer.

Data from the phase 1/2 CARDINAL trial support the breakthrough therapy designation for TERN-701 in this chronic myeloid leukemia population.

Experts discussed a case study involving a patient with multiple myeloma who developed CAR T-cell–related lymphomagenesis in the gastrointestinal tract.

In vivo CAR T-cell engineering represents a fundamental rethinking of how cellular therapies are produced and delivered.

Read this to learn 3 things you should know about the first-line treatment of mTNBC with TROP2-directed ADCs.

The safety profile of zocilurtatug pelitecan among patients with extrapulmonary neuroendocrine carcinomas was consistent with prior reports in SCLC.

Molecular testing and multidisciplinary care play a vital role in treating rare sarcomas, according to Steven Bialick, DO.

New trials reshape gastroesophageal adenocarcinoma care with durvalumab‑FLOT, HER2, and CLDN18.2 targets, plus practical toxicity tips.

Data presented at the 2026 AACR Annual Meeting highlighted promising therapeutic approaches in diseases such as NSCLC and oral premalignant lesions.

Penetration of molecular testing for non–small cell lung cancer in the US is not at 100%, according to Lyudmila Bazhenova, MD, FASCO.

Recently, conservative management has grown in popularity, especially among older patients and those with higher neighborhood-level socioeconomic status.

A panel of experts gathered to discuss the landscape of care in early-relapse multiple myeloma, new phase 3 data, and select patient cases.

The conditional marketing authorization for tovorafenib in pediatric patients with low-grade glioma harboring a BRAF alteration is based on data from the FIREFLY-1 trial.

Patrick A. Kenney, MD; and David A. Braun, MD, PhD, discussed parameters they use to determine a patient’s eligibility for cytoreductive nephrectomy.

According to Diane Simeone, MD, parallel investments in early screening and novel therapeutics can improve survival rates in pancreatic cancer.

The FDA has set a new Prescription Drug User Fee Act date of July 23, 2026, for subcutaneous isatuximab plus standard of care in multiple myeloma.

Sara Tolaney, MD, MPH, explored whether elacestrant can improve RFS vs standard endocrine therapy in patients with high-risk, ER+/HER2– early breast cancer.

Alex Herrera, MD, analyzed the SWOG S1826 trial, highlighting how nivolumab plus AVD improved survival and reduced AEs in advanced Hodgkin lymphoma.

Preliminary data from the phase 1/1b RMC-9805-001 study support continued development of zoldonrasib as a therapeutic strategy in this population.

Data from a phase 1 trial suggest that durable, vaccine-induced T-cell memory may be achievable even in pancreatic ductal adenocarcinoma.

Diane Simeone, MD, discussed results from the RASolute 302 trial, which showed improved overall survival with daraxonrasib vs SOC in metastatic PDAC.

Findings from a phase 1 trial showed no adverse effects higher than grade 3 among those who received ruxolitinib/abemaciclib for advanced myelofibrosis.

Updated interim data from a phase 1/2 study of the DR5 agonist ozekibart plus FOLFIRI demonstrated a 20% ORR and 87% DCR in late-line colorectal cancer.